Ex vivo analysis of T cell responses to peptides from RASGRP2, EBV and A. muciniphila showed these to be targets of responses in natalizumab-treated MS patients, indicating responses that had been primed in vivo and supporting their pathological relevance in this setting (71). This evidence concerns the gene RASGRP2 and myeloid sarcoma.